Lyell Immunopharma, Inc.
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…
Biotechnology
US, South San Francisco [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peers Performance
Similar Stocks · Adjusted CloseA quick analysis that compared Lyell Immunopharma, Inc. (LYEL) to it's peer group.
Peer Group
Loading...